
Opinion|Videos|January 17, 2025
Overview and Benefits of Port Delivery System with Ranibizumab
Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you provide an overview of the port delivery device with ranibizumab approved for treating neovascular AMD?
- How does the device function?
- What are the benefits of using the port delivery device with ranibizumab?
- Certainty of 6 months of continuous anti-VEGF delivery
- Patients in clinical trials prefer PDS over intravitreal injections
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
3
Study identifies 6 key genes linking air pollution to dry eye disease
4
Nanoscope Therapeutics releases positive long-term safety results from EXTEND study
5

















































.png)


